Type: mRNA vaccine
Status: Human trials of Thailand’s home-developed vaccine is set to start in October, the Thailand Board of Investment (BOI), the Asian nation’s economic development entity, said July 1. That date echoed a projection by Kiat Ruxrungtham, MD, scientific mentor and founder Chulalongkorn University’s Centre of Excellence in Vaccine Research and Development (Chula VRC), which was reported by Bloomberg News four days earlier. Chula VRC and the National Research Council of Thailand (NRCT) are spearheading development of the Thai vaccine, with support from Bangkok biotech company BioNet-Asia.
Thirteen monkeys have been injected with two of three planned injections, spaced monthly starting May 23, with the 13 being divided into low-dose, high-dose, and control cohorts, Ruxrungtham told Reuters a week earlier. Final results are expected in July. If successful, Chula VRC will order 10,000 doses for human trials.
Researchers in Thailand have partnered with investigators at the University of Pennsylvania to formulate the vaccine, which is similar to an undisclosed vaccine in development in the U.S. The vaccine will be developed at low cost, and will be provided to Pakistan and members of the Association of Southeast Asian Nations (ASEAN).
Thailand’s government has committed the nation to developing its own COVID-19 vaccine, determined not to repeat history; during the H1N1 outbreak in 2009, the government inked an agreement to procure a vaccine, but did not receive the vaccine until after the disease passed.
COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
● FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
● DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data.
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
● TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types: